Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells

Prostate

Volumn 78, Issue 13, 2018, Pages 953-961

  Al Saleh, Hassan A ^a   Haas Neill, Sandor ^a   Al Hashimi, Ali ^a   Kapoor, Anil ^a   Shayegan, Bobby ^a   Austin, Richard C ^a   Al Nedawi, Khalid ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

exosomes; fibrynolysis; microvesicles; PAI 1; TF

Indexed keywords

BLOOD CLOTTING FACTOR 10A; MESSENGER RNA; PROTEINASE ACTIVATED RECEPTOR 1; SHORT HAIRPIN RNA; THROMBIN; THROMBOPLASTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL CELL; ARTICLE; BIOASSAY; CHO CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DU145 CELL LINE; EGFRVIII GENE; EXOSOME; MOUSE; NONHUMAN; ONCOGENE; PHOTOMETRIC ASSAY; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; HUMAN; MALE; METABOLISM; METASTASIS; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; EXTRACELLULAR VESICLES; HUMANS; MALE; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTATIC NEOPLASMS; THROMBIN; THROMBOPLASTIN;

EID: 85047498756     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23653     Document Type: Article

References (40)

1. Lippi G, Plebani M, Franchini M, Guidi GC, Favaloro EJ. Prostate-specific antigen, prostate cancer, and disorders of hemostasis. Semin Thromb Hemost. 2009; 35:654–664.
2. de la Fouchardiere C, Flechon A, Droz JP. Coagulopathy in prostate cancer. Neth J Med. 2003; 61:347–354.
3. Adamson AS, Francis JL, Witherow RO, Snell ME. Coagulopathy in the prostate cancer patient: prevalence and clinical relevance. Ann R Coll Surg Engl. 1993; 75:100–104.
4. Duran I, Tannock IF. Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer. J Gen Intern Med. 2006; 21:C6–C8.
5. Van Hemelrijck M, Adolfsson J, Garmo H, et al. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol. 2010; 11:450–408.
6. Brose KM, Lee AY. Cancer-associated thrombosis: prevention and treatment. Curr Oncol. 2008; 15:S58–S67.
7. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood. 2007; 110:1723–1729.
8. Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie. 2012; 32:115–125.
9. Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg. 2009; 108:1433–1446.
10. Cale JM, Lawrence DA. Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent. Curr Drug Targets. 2007; 8:971–981.
11. Cale JM, Lawrence DA. Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent. Curr Drug Targets. 2007; 8:971–981.
12. Loreto MF, De Martinis M, Corsi MP, Modesti M, Ginaldi L. Coagulation and cancer: implications for diagnosis and management. Pathol Oncol Res. 2000; 6:301–312.
13. Donati MB, Gambacorti-Passerini C, Casali B, et al. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res. 1986; 46:6471–6474.
14. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005; 106:1604–1611.
15. Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis. 2006; 36:104–107.
16. Gerotziafas GT, Galea V, Mbemba E, et al. Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7. Thromb Res. 2012; 129:779–786.
17. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 1991; 51:3062–3066.
18. Gheldof D, Mullier F, Bailly N, et al. Microparticle bearing tissue factor: a link between promyelocytic cells and hypercoagulable state. Thromb Res. 2014; 133:433–439.
19. Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008; 10:619–624.
20. Balaj L, Lessard R, Dai L, Cho YJ, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commu. 2011; 1:180.
21. Lacroix R, Dignat-George F. Microparticles as a circulating source of procoagulant and fibrinolytic activities in the circulation. Thromb Res. 2012; 2:S27–S29.
22. Al-Nedawi K, Szemraj J, Cierniewski CS. Mast cell-derived exosomes activate endothelial cells to secrete plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc Biol. 2005; 25:1744–1749.
23. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci USA. 2009; 106:3794–3799.
24. Gabriel K, Ingram A, Austin R, et al. Regulation of the tumor suppressor pten through exosomes: a diagnostic potential for prostate cancer. PLoS ONE. 2013; 8:e70047.
25. Pettaway CA, Pathak S, Greene G, et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res. 1996; 2:1627–1636.
26. Read J, Ingram A, Saleh Al, et al. Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles. Eur J Cancer. 2017; 70:62–74.
27. Kim W, Zekas E, Lodge R, Susan-Resiga D, et al. Neuroinflammation-induced interactions between protease-activated receptor 1 and proprotein convertases in hiv-associated neurocognitive disorder. Mol Cell Biol. 2015; 35:3684–3700.
28. Al-Hashimi AA, Lebeau P, Majeed F, et al. Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. J Biol Chem. 2017; 292:21180–21192.
29. Szotowski B, Goldin-Lang P, Antoniak S, et al. Alterations in myocardial tissue factor expression and cellular localization in dilated cardiomyopathy. J Am Coll Cardiol. 2005; 45:1081–1089.
30. Al-Nedawi KN, Czyz M, Bednarek R, et al. Thymosin beta 4 induces the synthesis of plasminogen activator inhibitor 1 in cultured endothelial cells and increases its extracellular expression. Blood. 2004; 103:1319–1324.
31. Caldwell JA, Dickhout JG, Al-Hashimi AA, Austin RC. Development of a continuous assay for the measurement of tissue factor procoagulant activity on intact cells. Lab Invest. 2010; 90:953–962.
32. de la Fouchardiere C, Flechon A, Droz JP. Coagulopathy in prostate cancer. Neth J Med. 2003; 61:347–354.
33. May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005; 105:1734–1741.
34. Olapade-Olaopa EO, Moscatello DK, MacKay EH, et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer. 2000; 82:186–194.
35. Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res. 2006; 12:123–130.
36. Serafin A, Böhm L, Fernandez P, Achel D, Akudugu J. The potential of PAI-1 expression in needle biopsies as a predictive marker for prostate cancer. Cogent Med. 2016; 3:1183275.
37. Haubold K, Rink M, Spath B, et al. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost. 2009; 101:1147–1155.
38. Tantivejkul K, Loberg RD, Mawocha SC, et al. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem. 2005; 96:641–652.
39. Shi X, Gangadharan B, Brass LF, Ruf W, Mueller BM. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res. 2004; 2:395–402.
40. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013; 200:373–383.